Gosh, it’s been a busy few weeks! Our news cycle has been dominated by Lykos Therapeutics-related stories, from ICER’s report and panel meeting through to FDA’s Advisory Committee meeting and yesterday’s patent-related news.
Elsewhere in the psychedelics field, things have been a little quieter; especially for this author who was unable to attend the sixth edition of the Interdisciplinary Conference on Psychedelic Research (ICPR) in Haarlem.
Despite psychedelics companies taking a backseat on the news front as they let Lykos soak up the limelight—for better or worse—there are several headlines to share.
Let’s get you up to speed…
***
In this Issue
Lykos, Lykos, Lykos…
A First Look at EPIsoDE Trial Results
European Drug Report Briefly Discusses Psychedelics’ Potential Therapeutic Uses, Risks
DEA Should Improve Religious Exemption Petition Process, Says U.S. Government Accountability Office
Other Stories
Sign-in or join Pα+ to continue reading…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Subscribe AnnuallySubscribe Monthly
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space✓ Regular articles and deep dives across psychedelic research, policy and business✓ Interviews with insiders✓ Monthly interactive database and commentary on psychedelic patents✓ Quick-take analysis of major developments✓ A Library of primers and explainers✓ Access to our full back catalogue
Learn more about Pα+
